Mark Lowdell | CSO
INmuneBio

Mark Lowdell, CSO, INmuneBio

Appearances:



Day 2: 18th March 2026 @ 12:10

Critical considerations for successful ATMP development: Academic bench to commercial bedside

Mark Lowdell, CSO, INmuneBio

Day 2: 18th March 2026 @ 13:35

Panel Discussion: Autologous vs. Allogeneic Approaches

Moderator: Stefanos Theoharis, Chief Executive Officer, OneChain Immunotherapeutics
Mathias Kroll, Chief Business Officer, Cynata Therapeutics Ltd
Diana Hernandez, Director of Immune and Advanced Therapies, Anthony Nolan
Mark Lowdell, CSO, INmuneBio
Arthur Sagoskin, Chief Executive Officer & Co-Founder, Mygogenesis
Jiri Eitler, Group Leader - NK Cell Therapy, Dresden University of Technology
Salah Mansour, Associate Professor, iNKT Cell Therapy, University of Southampton
Dinesh Kundu, CEO, East Ocyon Bio Pvt. Ltd.
last published: 11/Jul/25 11:15 GMT

back to speakers


Get Involved with Advanced Therapies Congress

 

To sponsor or exhibit

Ashlea Foster
ashlea.foster@terrapinn.com
+44 208 164 3032

 

To speak

Chris Shanks
Chris.Shanks@terrapinn.com
+44 207 092 1150